SML1546

Sigma-Aldrich

SCR7 pyrazine

≥98% (HPLC)

Sinónimos:
2,3-Dihydro-6,7-diphenyl-2-thioxo-4(1H)-pteridinone, 6,7-Diphenyl-2-thio-lumazine (8CI)
Empirical Formula (Hill Notation):
C18H12N4OS
Número de CAS:
Peso molecular:
332.38
MDL number:
PubChem Substance ID:
En este momento no podemos mostrarle ni los precios ni la disponibilidad

Quality Level

assay

≥98% (HPLC)

form

powder

color

faintly yellow to dark yellow

solubility

DMSO: 10 mg/mL, clear

storage temp.

room temp

SMILES string

O=C(C1=C(N2)N=C(C3=CC=CC=C3)C(C4=CC=CC=C4)=N1)NC2=S

InChI

1S/C18H12N4OS/c23-17-15-16(21-18(24)22-17)20-14(12-9-5-2-6-10-12)13(19-15)11-7-3-1-4-8-11/h1-10H,(H2,20,21,22,23,24)

InChI key

GSRTWXVBHGOUBU-UHFFFAOYSA-N

General description

SCR7 pyrazine is an inhibitor of DNA ligase IV.

Application

SCR7 pyrazine has been used as a non-homologous end joining (NHEJ) modulator to study its effect on CRISPR/Cas9-mediated editing.
SCR7 pyrazine has been shown to enhance CRISPR genome editing efficiency. To see other small molecule CRISPR enhancers, visit sigma.com/CRISPR-enhancers.

Packaging

5, 25 mg in glass bottle

Biochem/physiol Actions

SCR7 pyrazine is reported to be an inhibitor of non-homologous end joining (NHEJ) and has been shown to enhance the efficiency of CRISPR-Cas9 genome editing. The effect of SCR7 pyrazine on the efficiency and targeting precision of CRISPR applications has been shown to be cell type specific and context dependent. SCR7 pyrazine is a product of spontaneous cyclization of SCR7, first reported by Srivastava, M., et al.

pictograms

Exclamation mark

signalword

Warning

hcodes

RIDADR

NONH for all modes of transport

WGK Germany

WGK 3

Flash Point F

Not applicable

Flash Point C

Not applicable

Yuanwu Ma et al.
RNA biology, 13(7), 605-612 (2016-05-11)
Precise modifications such as site mutation, codon replacement, insertion or precise targeted deletion are needed for studies of accurate gene function. The CRISPR/Cas9 system has been proved as a powerful tool to generate gene knockout and knockin animals. But the...
Justin Moser et al.
Proceedings of the National Academy of Sciences of the United States of America, 115(35), E8219-E8227 (2018-08-17)
The Restriction Point was originally defined as the moment that cells commit to the cell cycle and was later suggested to coincide with hyperphosphorylation of the retinoblastoma protein (Rb). Current cell cycle models posit that cells exit mitosis into a...
Mrinal Srivastava et al.
Cell, 151(7), 1474-1487 (2012-12-25)
DNA Ligase IV is responsible for sealing of double-strand breaks (DSBs) during nonhomologous end-joining (NHEJ). Inhibiting Ligase IV could result in amassing of DSBs, thereby serving as a strategy toward treatment of cancer. Here, we identify a molecule, SCR7 that...
Diane Yang et al.
Scientific reports, 6, 21264-21264 (2016-02-19)
Efficient gene editing is essential to fully utilize human pluripotent stem cells (hPSCs) in regenerative medicine. Custom endonuclease-based gene targeting involves two mechanisms of DNA repair: homology directed repair (HDR) and non-homologous end joining (NHEJ). HDR is the preferred mechanism...
Disruption of diphthamide synthesis genes and resulting toxin resistance as a robust technology for quantifying and optimizing CRISPR/Cas9-mediated gene editing.
Killian T, et al.
Scientific Reports, 7(1), 15480-15480 (2017)
Artículos
The CRISPR-Cas9 system is an RNA-guided genome-editing tool that provides researchers a simple, easy, and quick way to modify the genomes of various organisms.
Más información

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.